Veeva Systems (NYSE:VEEV) 2025 Earnings Call Presentation

Vision and Strategy - Veeva is aiming for $6 billion in revenue by 2030[8, 13], and is on track to achieve this goal[8, 13, 54, 66, 87] - The company estimates a $20 billion+ total addressable market (TAM) in Life Sciences[10, 70], with approximately 16% penetrated as of FY26E[10, 70] - Veeva AI is expected to be a significant growth driver[8, 30, 53] Financial Performance and Guidance - Q3'26 total revenue guidance is $790-$793 million, with subscription revenue of approximately $671 million[62] - Q3'26 non-GAAP operating income is projected at $348-$350 million, and non-GAAP fully diluted net income per share at $1.94-$1.95[62] - The company's revenue run rate today is $3.2 billion, with a goal of $6 billion by 2030[67] Market Segmentation and Growth - Biopharma accounts for 92% of Veeva's revenue, MedTech for 5%, and other industries for 3%[65] - The subscription revenue mix is currently 84%, with a target of approximately 87% by 2030[67] - Veeva is experiencing continued adoption in R&D, with an increasing number of customers using multiple products[94, 95]